SOLID-TIMI 52

SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.

MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome

PRESENTATIONS

TIMI 52 Slides
SOLID Ceramides (Gencer AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)

PUBLICATIONS

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial

Metabolic Syndrome And The Risk Of Adverse Cardiovascular Events After An Acute Coronary Syndrome: Insights From SOLID-TIMI 52 Trial

Adverse Limb Events in Patients With Peripheral Artery Disease Presenting With Acute Coronary Syndrome: Observations From SOLID-TIMI 52

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Interleukin-6 And The Risk Of Adverse Outcomes In Patients After An Acute Coronary Syndrome: Observations From The SOLID-TIMI 52 Trial

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials

Cystatin C Is Associated With The Risk Of Adverse Outcomes Independent Of Established And Novel Cardiorenal Markers: An Analysis From The SOLID-TIMI 52 Trial

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

Growth Differentiation Factor-15 (GDF-15) for Risk Stratification in Patients After an Acute Coronary Syndrome: Insights From the SOLID-TIMI 52 Trial

Performance Reports And The Utilization Of Guideline-Based Therapies In A Large Clinical Trial Population Enrolled After An Acute Coronary Syndrome: Insights From The SOLID-TIMI 52 Trial

Galectin-3 For Heart Failure Risk Stratification In Patients After Acute Coronary Syndromes (ACS): Insights From The SOLID-TIMI 52 Trial

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events

Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome